| P2093 | author name string | Abbot F Clark | |
| | Thomas Yorio | |
| P2860 | cites work | A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy | Q22009991 |
| | Identification of the gene responsible for Best macular dystrophy | Q24315031 |
| | A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy | Q24324625 |
| | Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies | Q28142484 |
| | An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration | Q28190470 |
| | Retinal degeneration mutants in the mouse | Q28202375 |
| | Characterization of RGS5 in regulation of G protein-coupled receptor signaling | Q28205108 |
| | Expression of optineurin, a glaucoma-linked gene, is influenced by elevated intraocular pressure | Q28207484 |
| | Adult-onset primary open-angle glaucoma caused by mutations in optineurin | Q28217964 |
| | Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy | Q28236562 |
| | Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes. | Q30640405 |
| | Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model | Q30656714 |
| | Genetic linkage of familial open angle glaucoma to chromosome 1q21–q31 | Q57785250 |
| | BIOMEDICINE: Enhanced: A New Angle on Ocular Development | Q58541580 |
| | Development of experimental chronic intraocular hypertension in the rabbit | Q67592156 |
| | Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis | Q71225091 |
| | Assessing retinal neovascularization in an animal model of proliferative retinopathy | Q71544965 |
| | Programmed cell death of retinal ganglion cells during experimental glaucoma | Q71735807 |
| | Chronic ocular hypertension following episcleral venous occlusion in rats | Q71735886 |
| | Experimental glaucoma damage mechanism | Q71819058 |
| | The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators | Q73055302 |
| | A rat model of chronic pressure-induced optic nerve damage | Q73202589 |
| | Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells | Q73258549 |
| | Age-related permeability changes in rabbit corneas | Q73299506 |
| | Essential role of growth hormone in ischemia-induced retinal neovascularization | Q73407423 |
| | Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit | Q74522699 |
| | Variations in the myocilin gene in patients with open-angle glaucoma | Q74740868 |
| | Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor | Q77334697 |
| | Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine | Q77729873 |
| | Advances in glaucoma therapeutics | Q81911624 |
| | AL-3789: a novel ophthalmic angiostatic steroid | Q94447066 |
| | Selective photoreceptor damage in albino rats using continuous blue light. A protocol useful for retinal degeneration and transplantation research. | Q50509862 |
| | An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. | Q50983673 |
| | Incidence of age-related cataract over a 10-year interval: the Beaver Dam Eye Study. | Q53667262 |
| | The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. | Q53872479 |
| | Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A) | Q53956831 |
| | Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. | Q54178097 |
| | Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration | Q57784990 |
| | An update on photodynamic therapy in age-related macular degeneration | Q30710464 |
| | Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. | Q30824036 |
| | Medical backgrounders: glaucoma. | Q30886319 |
| | Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey | Q30990645 |
| | Intravitreal triamcinolone for refractory diabetic macular edema | Q31050662 |
| | Changing times for the management of diabetic retinopathy | Q31123332 |
| | The potential role of PKC beta in diabetic retinopathy and macular edema | Q31123344 |
| | Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. | Q31759435 |
| | Characterization of a transformed rat retinal ganglion cell line | Q31878268 |
| | Experimental glaucoma model in the rat induced by laser trabecular photocoagulation after an intracameral injection of India ink. | Q31971182 |
| | AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse | Q32125104 |
| | A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs | Q33640954 |
| | Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma | Q33693579 |
| | An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy | Q33693592 |
| | Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma | Q33706025 |
| | Anterior ocular infections: an overview of pathophysiology and treatment | Q33838932 |
| | Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function | Q34012751 |
| | Myocilin glaucoma | Q34167417 |
| | Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. | Q34207821 |
| | Biodegradable polymers for ocular drug delivery | Q34243417 |
| | Physiological approaches to neuroprotection. boosting of protective autoimmunity | Q34264120 |
| | Fluoroquinolones: place in ocular therapy | Q34277806 |
| | Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. | Q34378842 |
| | The treatment of dry eye. | Q34391944 |
| | Identification of a gene that causes primary open angle glaucoma. | Q34414141 |
| | Transscleral drug delivery for posterior segment disease | Q34416367 |
| | Molecular genetics of age-related macular degeneration | Q34416730 |
| | A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: molecular cloning, tissue expression, and chromosomal mapping | Q34427530 |
| | Animal models in research on retinal degenerations: past progress and future hope | Q34537525 |
| | Genetic basis of glaucoma | Q34553228 |
| | Serum autoantibodies in patients with glaucoma | Q34559906 |
| | Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. | Q34600427 |
| | Update on ocular allergy treatment | Q34628611 |
| | Matrix metalloproteinases in disease and repair processes in the anterior segment. | Q34674433 |
| | Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. | Q34677464 |
| | Glaucomatous optic neuropathy: mechanisms of disease | Q34684506 |
| | Mechanisms of age-related macular degeneration. | Q34684544 |
| | Gene therapy for retinal and choroidal diseases | Q34701404 |
| | Ocular preparations: the formulation approach | Q34721415 |
| | Ocular allergy guidelines: a practical treatment algorithm | Q34730735 |
| | Endothelin: is it a contributor to glaucoma pathophysiology? | Q34760872 |
| | Myocilin and glaucoma: facts and ideas. | Q34768697 |
| | Genetic animal models for retinal degeneration | Q34772735 |
| | A role for local inflammation in the formation of drusen in the aging eye. | Q34809064 |
| | Diabetic retinopathy: more than meets the eye. | Q35036623 |
| | Mechanisms for monitoring changes in retinal status following therapeutic intervention in diabetic retinopathy | Q35036626 |
| | Managing cystoid macular edema after cataract surgery | Q35052247 |
| | A new view of diabetic retinopathy: a neurodegenerative disease of the eye. | Q35092253 |
| | Five year incidence of cataract surgery: the Blue Mountains Eye Study. | Q35590565 |
| | Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model | Q35789316 |
| | Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma | Q36440373 |
| | Laser-induced primate glaucoma. I. Progression of cupping | Q36612626 |
| | Early changes in matrix metalloproteinases and inhibitors afterin vitrolaser treatment to the trabecular meshwork | Q36684737 |
| | Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases | Q37362821 |
| | Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy | Q37607034 |
| | Mechanisms of optic nerve damage in primary open angle glaucoma | Q40640046 |
| | Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa | Q40764969 |
| | Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor | Q40832933 |
| | A cellular assay distinguishes normal and mutant TIGR/myocilin protein | Q40920038 |
| | Opportunistic infections of the eye in immunocompromised patients | Q41378989 |
| | Ocular actions of endothelins | Q41463127 |
| | Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies | Q41607468 |
| | Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids | Q42555516 |
| | Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice | Q42665432 |
| | Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. | Q42794620 |
| | Response of experimental retinal neovascularization to thiazolidinediones | Q43603007 |
| | Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats | Q43619965 |
| | Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. | Q43760620 |
| | Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration | Q43943551 |
| | Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model | Q44003999 |
| | Levobetaxolol-induced Up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy | Q44036087 |
| | Retinal metabolic abnormalities in diabetic mouse: comparison with diabetic rat. | Q44108814 |
| | Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization | Q44108830 |
| | Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. | Q44763476 |
| | Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain | Q44799120 |
| | Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells | Q46096320 |
| | Analysis of myocilin mutations in 1703 glaucoma patients from five different populations | Q46636264 |
| | Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells | Q46769376 |
| P433 | issue | 6 | |
| P921 | main subject | drug discovery | Q1418791 |
| P304 | page(s) | 448-459 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Ophthalmic drug discovery | |
| P478 | volume | 2 | |